ROCKVILLE, MD – There is a need for the scientific community to explore the use of additional strength biowaivers for modified release (MR) drugs given the increasing market demand for these “patient ...
Objective: To evaluate pharmaceutical and pharmacotherapeutic differences in oral opioid modified-release products used in the management of chronic pain. Data Sources: Searches of MEDLINE (1966-May ...
The European Medicines Agency (EMA) has released two new draft guidelines on, respectively, the quality of oral modified release products and transdermal patches. The two draft guidance documents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results